Sept 9 (Reuters) - Recordati Industria Chimica e Farmaceutica SpA RECI.MI :
* Company's unit Orphan Europe says Health Canada has granted market authorization for
Carbaglu
* Authorization for Carbaglu was granted as an adjunctive therapy for the treatment of acute
hyperammonemia (high blood level of ammonia) or as a maintenance therapy for chronic
hyperammonemia due to the deficiency of the hepatic enzyme N-aceytlglutamate synthase (NAGS) in
pediatric and adult patients
* Carbaglu will be imported and distributed in Canada by unit Recordati Rare Diseases Inc
Source text: http://bit.ly/1g8R5bs
Further company coverage: RECI.MI
(Gdynia Newsroom)